ENSYSCE BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $12.22 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2023-03-30
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2021-12-31 was $11.44M.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2022 was $12.22M, a 31.24% decline from fiscal 2021.
- ENSYSCE BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2021 was $17.77M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $12.22M 10-K · filed 2023-03-30 | |
| 2022-09-30 | $12.22M 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | $11.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $17.77M 10-K · filed 2022-03-31 | |
| 2021-09-30 | $6.33M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |